Back to Search
Start Over
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA(r) (loncastuximab tesirine-lpyl) in Europe and Select International Territories
- Source :
- European Union News. July 9, 2022
- Publication Year :
- 2022
-
Abstract
- LAUSANNE: ADC Therapeutics SA has issued the following press release: ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- European Union News
- Publication Type :
- News
- Accession number :
- edsgcl.710172050